Skip to content

Vorinostat

Histone Deacetylase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: suberoylanilide hydroxamic acid

OnpFDA approvedOrphan designationATC L01XH01

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Vorinostat is an onp drug in the Histone Deacetylase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2006. Its mechanism of action is classified as Histone Deacetylase Inhibitors. DrugCentral lists 32 molecular targets, including HDAC6, HDAC1 and HDAC2. Recorded indications include Primary cutaneous T-cell lymphoma.

  • Approval status: onp (first approved 2006 by the FDA).
  • Drug class: Histone Deacetylase Inhibitor.
  • Mechanism of action: Histone Deacetylase Inhibitors.
  • Molecular targets: HDAC6, HDAC1, HDAC2 and HDAC3|NCOR2 (32 listed in DrugCentral).
  • Indications: Primary cutaneous T-cell lymphoma.
  • ATC code: L01XH01 (Histone deacetylase (HDAC) inhibitors).
  • Molecular formula: C14H20N2O3; molecular weight 264.32 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Primary cutaneous T-cell lymphoma

Contraindications (18)

  • Anemia
  • Breastfeeding (mother)
  • Congenital long QT syndrome
  • Deep venous thrombosis
  • Dehydration
  • Diabetes mellitus
  • Diarrhea
  • Disease of liver
  • Hyperglycemia
  • Hypocalcemia
  • Hypokalemia
  • Hypomagnesemia
  • Pregnancy, function
  • Prolonged QT interval
  • Pulmonary thromboembolism
  • Thrombocytopenic disorder
  • Thromboembolic disorder
  • Vomiting

Mechanism & targets

Mechanism of action (MoA)Histone Deacetylase Inhibitors
Established pharmacologic classHistone Deacetylase Inhibitor

Molecular targets (32)

TargetGeneActionActivity
Histone deacetylase 6HDAC6inhibitorKi 9.00
Histone deacetylase 1HDAC1inhibitorKi 8.89
Histone deacetylase 2HDAC2inhibitorKi 8.80
Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2)HDAC3|NCOR2unknownKi 8.70
Histone deacetylase 3HDAC3inhibitorKi 8.30
Histone deacetylase (HDAC1 and HDAC2)HDAC1|HDAC2unknownIC50 8.00
Histone deacetylaseHDAC3|HDAC4|HDAC1|HDAC7|HDAC2|HDAC10|HDAC11|HDAC8|HDAC6|HDAC9|HDAC5unknownIC50 8.00
Bromodomain-containing protein 4BRD4unknownIC50 8.00
Histone deacetylase 3/NCoR1HDAC3|NCOR1unknownKi 7.92
Histone deacetylase 11HDAC11unknownKi 7.89
Histone deacetylase 4HDAC4unknownKi 7.80
Histone deacetylasehd1bunknownIC50 7.55
Histone deacetylase 5HDAC5unknownKi 7.48
Histone deacetylase 9HDAC9unknownKi 7.31
HD2 type histone deacetylase HDA106; Histone deacetylase 2b; Uncharacterized proteinhda106unknownIC50 7.30
Histone deacetylase 10HDAC10unknownKi 7.30
Histone deacetylaseHDAC1unknownIC50 7.23
Histone deacetylasePfHDAC1unknownIC50 7.00
Histone deacetylase 1/3/5/8HDAC3|HDAC1|HDAC8|HDAC5unknownIC50 6.96
Histone deacetylase 1Hdac1unknownIC50 6.95

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2006-10-06FDA—MERCKYes

ATC classification

ATC codeTherapeutic hierarchy
L01XH01ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Histone deacetylase (HDAC) inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Febrile neutropenia283.7
Thrombocytopenia173.0
Product use in unapproved indication129.5
Electrocardiogram QT prolonged107.5
Lymphopenia91.2
Dehydration91.1
Torsade de pointes89.0
Anaemia79.5
Platelet count decreased74.6
Sepsis73.2
Neutropenia67.5
Cutaneous T-cell lymphoma65.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vorinostat is on its molecule page.

Molecular formulaC14H20N2O3
Molecular weight264.32 g/mol
CAS number149647-78-9
InChIKeyWAEXFXRVDQXREF-UHFFFAOYSA-N
PubChem CID5311
ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vorinostat used for?

DrugCentral lists the following indications for Vorinostat: Primary cutaneous T-cell lymphoma.

How does Vorinostat work?

Vorinostat is classified as Histone Deacetylase Inhibitors; its molecular targets in DrugCentral include HDAC6 (inhibitor), HDAC1 (inhibitor), HDAC2 (inhibitor) and HDAC3|NCOR2.

When was Vorinostat first approved?

Vorinostat was first approved by the FDA in 2006.

What drug class does Vorinostat belong to?

Vorinostat is in the Histone Deacetylase Inhibitor class.

What is the chemical formula of Vorinostat?

Vorinostat has the molecular formula C14H20N2O3 and a molecular weight of 264.32 g/mol.

Browse: all drugs starting with V · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2006-10-06
AgencyFDA
Targets32
Indications1
FormulaC14H20N2O3
DrugCentral ID4124
Interactive profile